A Signal-to-Noise Ratio is No Subsitute for a Brain - The relevance of control charts to signal-to-noise ratio - BioPharm International

ADVERTISEMENT

A Signal-to-Noise Ratio is No Subsitute for a Brain
The relevance of control charts to signal-to-noise ratio


BioPharm International
Volume 19, Issue 3

The chart of S/NT shown in Figure 2 uses a value of 50 for the target; the two charts are very similar. The S/NT value on the upper limit of 39.3 has a volume precisely on the target and a small standard deviation of 0.542.

The signal-to-noise ratio used by McAllister is set out in the following equation:.















in which T is the target.

For convenience, our laboratory reports of the volume or weight of drug dispensed present a concise summary of the information on the performance of each batch. This summary consists of the mean, the coefficient of variation, and the minimum and maximum of 375 individual measurements. This summary provides all the relevant information contained in the individual three replicate measurements of 125 packs.














































The absence of raw data is not a problem because we can calculate S2 T by modifying Equation (1) as follows:














The standard deviation Sx can be estimated by multiplying the coefficient of variation (CV) by the mean or by dividing the range (R) by a constant (d 2 ) that depends on sample size. Values of d 2 are available in reference books such as Wheeler and Chambers (1992). Some values of d 2 are: 1.128 for n = 2, 1.693 for n = 3, 3.078 for n = 10 and 3.735 for n = 20. For a sample of 375 (3 repeats x 125 valves), the value of d 2 is 5.90.

Presenting S/NT in the form of Equation 2 may make it easier to understand what the signal-to-noise ratio tells us about the process. We can see that the term 20 * log10 T, which = 33.979 if T = 50, can be regarded as a baseline.

The second term,















blog comments powered by Disqus

ADVERTISEMENT

Moscow Hosts IFPMA Biosimilars Conference
May 17, 2013
AbbVie and Alvine Will Collaborate on Celiac Disease Therapy
May 15, 2013
FDA Issues Pharmacoepidemiologic Safety Study Guidance
May 14, 2013
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
May 13, 2013
Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International,
Click here